Braftovi access in the United Arab Emirates: the EDE named-patient pathway

Last reviewed 2026-05-12 by the Reserve Meds clinical and regulatory team. This page combines the UAE country research module with the Braftovi drug module to describe the path families actually walk.

Quick orientation

Braftovi (encorafenib) is an oral selective BRAF kinase inhibitor originally developed by Array BioPharma and now marketed by Pfizer. The US Food and Drug Administration approved Braftovi in June 2018 in combination with binimetinib (Mektovi) for unresectable or metastatic BRAF V600E or V600K-mutant melanoma, in April 2020 in combination with cetuximab for BRAF V600E-mutant metastatic colorectal cancer after prior therapy, and in October 2023 in combination with binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer. The standard daily dose is 450 mg in melanoma and 300 mg in colorectal cancer, given as 75 mg capsules. Reserved for you.

Why UAE patients need Braftovi via a named-patient pathway

BRAF V600 mutations occur in approximately 50 percent of cutaneous melanoma and approximately 5 to 10 percent of metastatic colorectal cancer, with smaller fractions in NSCLC and other tumour types. UAE oncology services routinely test for BRAF mutations as part of the standard molecular workup. The locally available BRAF-targeted combination in the UAE is typically the GSK pair (dabrafenib plus trametinib), which holds an established MoHAP registration. The case for Braftovi specifically is built when the treating oncologist wants the Pfizer pair (encorafenib plus binimetinib) for its dosing pattern, when the patient has not tolerated the dabrafenib-trametinib combination, when the patient is being treated for a metastatic colorectal cancer indication that uses the encorafenib-cetuximab pairing, or when the lung cancer indication is in scope.

Braftovi is not consistently held in UAE federal stock at the level the GSK pair enjoys. The EDE named-patient pathway is the established route when the molecular oncology workup supports the BRAF V600E-positive diagnosis and the treating oncologist has documented the clinical case for encorafenib specifically.

The EDE / MoHAP named-patient pathway applied to Braftovi

The federal pathway for a UAE-licensed physician to obtain a medicine that is not registered or not stocked locally is the unregistered-medicine import permit, administered through the Emirates Drug Establishment (EDE) at ede.gov.ae. The EDE took over 44 core services from MoHAP under Federal Decree-Law No. 38 of 2024. The framework allows hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority such as the US FDA and a locally registered alternative is not suitable.

For Braftovi, the clinical justification packet rests on the molecular pathology report. The treating oncologist documents the cancer diagnosis (cutaneous melanoma, metastatic colorectal cancer, or NSCLC), the molecular pathology confirmation of BRAF V600E or V600K mutation by a CAP-accredited or comparable laboratory, the staging workup, the prior systemic therapy trail (immunotherapy line for melanoma, FOLFOX or FOLFIRI backbone for colorectal, prior platinum chemotherapy for NSCLC where applicable), and the rationale for the encorafenib-containing regimen (combination partner identified: binimetinib for melanoma and NSCLC, cetuximab for colorectal cancer).

A complete EDE application for Braftovi typically includes the oncologist's clinical justification letter, the molecular pathology report, the treating physician's MoHAP, DHA, DoH, or Sharjah Health Authority licence verification, an anonymised patient identifier, full product details (Braftovi 75 mg capsules), the destination dispensing pharmacy name with licence number and pharmacy in charge, and the patient informed consent. Where the combination partner is also unregistered or unstocked, the application is structured as a coordinated submission. Approval timelines for routine cases are 5 to 15 business days. Complex submissions extend to 4 to 6 weeks.

Where Braftovi gets dispensed in the UAE

Braftovi is an oral capsule with standard ambient storage at 20 to 25 degrees Celsius. The dispensing site is the outpatient oncology pharmacy attached to the treating cancer centre. The most natural dispensing sites are the oncology services at Cleveland Clinic Abu Dhabi, the Tawam Hospital National Reference Cancer Centre in Al Ain, Sheikh Khalifa Medical City, American Hospital Dubai (Mayo Clinic Care Network member), Mediclinic City Hospital in Dubai Healthcare City, and the NMC Royal Hospital network. The treating multidisciplinary tumour board typically directs the dispensing site selection.

Real cost picture for Braftovi in the UAE

The US wholesale acquisition cost for Braftovi alone is approximately USD 14,000 to 18,000 per month at the 450 mg daily melanoma dose, translating to approximately AED 51,000 to 66,000 monthly at the 3.67 peg. The 300 mg daily colorectal cancer dose runs proportionally lower. The figure is the encorafenib acquisition cost only. The combination partner (binimetinib or cetuximab) adds separately and typically dominates the colorectal cancer regimen cost.

All-in delivered cost stacks the drug acquisition, international logistics (USD 400 to 800 per shipment, ambient), EDE handling and customs (USD 300 to 600 per case), the dispensing pharmacy fee, and the Reserve Meds concierge coordination fee. Where the combination partner is also imported, the logistics consolidation is structured into a single coordinated shipment to minimise stacking. Insurance in the UAE handles oncology biologics and targeted therapies case by case. Pre-authorisation is the norm. Thiqa, administered by Daman for UAE nationals in Abu Dhabi, has the broadest specialty coverage. Daman, GIG Gulf, Sukoon, ADNIC, and Orient each assess oncology cases individually. We do not promise coverage.

Typical timeline for Braftovi in the UAE

The EDE permit processes in 5 to 15 business days for a routine submission with a clear molecular pathology rationale and a well-defined combination partner. International logistics adds 3 to 7 business days for ambient-shipped oral oncology agents. Customs clearance is typically 1 to 3 business days. A patient who completes the documentation in week one typically receives the first cycle in week three to week five. Subsequent cycles are coordinated to a 28-day rhythm with the oncology team and the combination partner schedule.

What your physician needs to provide

The clinical justification letter for a Braftovi EDE submission carries the standard solid-tumour-targeted-therapy structure. The treating oncologist's letter typically addresses the cancer diagnosis with stage and prior therapy, the molecular pathology confirmation of BRAF V600E or V600K (laboratory report attached), the indication-specific combination partner rationale (encorafenib plus binimetinib for melanoma and NSCLC, encorafenib plus cetuximab for colorectal cancer), the prior systemic therapy trail and outcomes, the rationale for switching to or initiating the encorafenib-containing regimen, and the dose proposal (450 mg daily in melanoma and NSCLC, 300 mg daily in colorectal cancer).

The molecular pathology laboratory report is attached. The patient informed consent reflects the targeted-therapy adverse-event profile (cutaneous adverse events including squamous cell carcinoma and keratoacanthoma, ophthalmic events including uveitis, cardiac QT prolongation, and the combination partner's specific profile). The treating physician's licence must be in active standing in the emirate of the dispensing facility (MoHAP for the Northern Emirates, DHA for Dubai, DoH for Abu Dhabi and Al Ain, Sharjah Health Authority for Sharjah).

Pharmacovigilance considerations

Encorafenib is metabolised primarily by CYP3A4 and is a sensitive substrate for CYP3A4 inhibitors and inducers. The US label includes specific dose adjustment guidance for concurrent strong or moderate CYP3A4 modulators. The cutaneous adverse-event profile of the BRAF-MEK combination requires baseline and periodic dermatology assessment. QT monitoring is part of the standard schedule. Pharmacovigilance follow-up is structured around monthly clinical assessment with ECG and laboratory work as the protocol specifies. Adverse events identified by the treating team route to the Pfizer safety reporting channel and to the EDE post-market surveillance address.

Common questions about Braftovi in the UAE

Why Braftovi rather than dabrafenib (Tafinlar) plus trametinib (Mekinist)? The two BRAF-MEK combinations are clinically active in BRAF V600-mutant melanoma. The dabrafenib-trametinib pair has the longer regional history and is more widely stocked. The encorafenib-binimetinib pair has a once-daily encorafenib component and a different adverse-event distribution. For colorectal cancer, Braftovi is paired with cetuximab rather than a MEK inhibitor, which is the regimen specifically supported by the US label and is structurally different from any melanoma regimen. The clinical choice rests with the treating oncology team.

Will Daman, Thiqa, or my private insurer cover this? Each insurer assesses oncology cases case by case. Pre-authorisation is the norm. Thiqa has the broadest specialty coverage in Abu Dhabi. We do not promise coverage.

Is Braftovi a controlled substance? No. Braftovi is not a DEA scheduled substance.

Can Braftovi be dispensed without the combination partner? The US label use is in combination. Single-agent encorafenib is not the approved use. The treating oncologist defines the combination at the EDE submission.

What patients and families ask when they first call

"How does the case actually start?" The patient, family, or treating oncologist contacts Reserve Meds through the waitlist form. Within 24 to 48 hours, a coordinator confirms eligibility (the molecular pathology BRAF V600 confirmation is the central screening question), sends the documentation kit to the physician, and outlines the EDE submission sequence. No payment is taken at this stage.

"What if we have only the histopathology, not the molecular pathology?" A BRAF V600E or V600K confirmation by an accredited molecular pathology laboratory is the gate for Braftovi. If the patient has the histopathology only, the treating oncology team typically arranges reflex BRAF testing on the existing tissue block before any EDE submission is pursued. Reserve Meds can confirm laboratory options regionally.

"How does the combination partner logistics work?" Where the combination partner (binimetinib for melanoma and NSCLC, cetuximab for colorectal cancer) is also imported, the EDE submission is structured as a coordinated package and the logistics consolidate into a single shipment cycle. The coordinator manages the consolidation so the patient is not waiting for one drug while the other has arrived.

"What does the dermatologic adverse-event monitoring look like?" The BRAF-MEK combination carries a recognised risk of cutaneous adverse events including squamous cell carcinoma and keratoacanthoma. The US label and most regional oncology services structure dermatology assessment at baseline, at the end of cycle 1, then at 2-month intervals during therapy. The treating oncology team coordinates dermatology referral.

Where Reserve Meds fits in Braftovi cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating oncologist, the EDE, or the dispensing pharmacy. For a Braftovi case, our work is the regulatory documentation assembly, the US-side procurement coordination with the Pfizer specialty distributor, the coordinated logistics for the combination partner where also imported, the customs handoff, and a single named coordinator for the patient through the multi-month treatment course. Reserved for you.

Documentation kit for the treating oncology team

The documentation kit Reserve Meds sends the treating oncology team after a waitlist confirmation contains the EDE clinical-justification letter template tailored to the BRAF-targeted regimen and the indication-specific combination partner, the molecular pathology capture sheet (BRAF V600E or V600K with laboratory report), the prior systemic therapy capture sheet, the indication-specific dose proposal (450 mg daily for melanoma and NSCLC, 300 mg daily for colorectal cancer), the dermatology surveillance schedule template, the QT and cardiac monitoring template, the patient informed consent template covering the targeted-therapy adverse-event profile, the dispensing pharmacy intake checklist for the combination supply, and the post-cycle adverse-event capture sheet. The kit is built so the oncology team focuses on the patient conversation and the multidisciplinary tumour board coordination.

Next step

If a treating oncologist in the UAE has a confirmed BRAF V600-mutant tumour and is weighing the Braftovi-containing regimen, the waitlist is the first step. We respond within 24 to 48 hours with an eligibility confirmation and a documentation kit for the physician.

Join the Braftovi waitlist

Reserved for you.

Related

• Braftovi clinical resource
• Melanoma
• Colorectal cancer
• United Arab Emirates country page

Sources

1. FDA approval, Braftovi (encorafenib), Pfizer (originally Array BioPharma), approvals June 2018 (melanoma), April 2020 (colorectal cancer), October 2023 (NSCLC).
2. UAE Federal Decree-Law No. 38 of 2024 and the Emirates Drug Establishment portal at ede.gov.ae.
3. Pfizer US prescribing information for Braftovi (encorafenib), 75 mg capsules; 450 mg daily melanoma and